Enoyl-[acyl-carrier-protein] reductase [NADH] FabI · SINGLE PROTEIN · Bacteria
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Enoyl-[acyl-carrier-protein] reductase [NADH] FabI shows late clinical disease relevance led by allergic disease. 4 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P0AEK4. Start with allergic disease, then reuse UniProt P0AEK4 as the stable protein anchor across project notes and exports.
Start with allergic disease, then reuse UniProt P0AEK4 as the stable protein anchor across project notes and exports.
Enoyl-[acyl-carrier-protein] reductase [NADH] FabI shows late clinical disease relevance led by allergic disease. 4 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with allergic disease because it currently carries late clinical support. Linked drugs include TRICLOSAN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyEnoyl-[acyl-carrier-protein] reductase [NADH] FabI
Review this target as Enoyl-[acyl-carrier-protein] reductase [NADH] FabI, mapped to UniProt P0AEK4. Sequence length is 262 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Enoyl-[acyl-carrier-protein] reductase [NADH] FabI as ChEMBL target CHEMBL2364678, mapped to UniProt P0AEK4. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Enoyl-[acyl-carrier-protein] reductase [NADH] FabI is the right protein anchor across sources, using UniProt P0AEK4 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why allergic disease is currently framed as late clinical support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Enoyl-[acyl-carrier-protein] reductase [NADH] FabI |
| Target Type | SINGLE PROTEIN |
| Organism | Bacteria |
| UniProt | P0AEK4 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Enoyl-[acyl-carrier-protein] reductase [NADH] FabI |
| UniProt Accession | P0AEK4 |
| Component Type | Protein |
| Sequence Length | 262 aa |
Enoyl-[acyl-carrier-protein] reductase [NADH] FabI
Review this target as Enoyl-[acyl-carrier-protein] reductase [NADH] FabI, mapped to UniProt P0AEK4. Sequence length is 262 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Enoyl-[acyl-carrier-protein] reductase [NADH] FabI shows late clinical disease relevance led by allergic disease. 4 more disease programs remain visible in the same review block.
Start review with allergic disease because it currently carries late clinical support. Linked drugs include TRICLOSAN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.